Literature DB >> 7978900

Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history.

E P Krenning1, P P Kooij, W H Bakker, W A Breeman, P T Postema, D J Kwekkeboom, H Y Oei, M de Jong, T J Visser, A E Reijs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7978900     DOI： 10.1111/j.1749-6632.1994.tb17300.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  55 in total

1.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.

Authors:  Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

2.  The efficacy of (177)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis.

Authors:  Seong-Jang Kim; Kyoungjune Pak; Phillip J Koo; Jennifer J Kwak; Samuel Chang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-09       Impact factor: 9.236

3.  Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment.

Authors:  Mohammadali Hamiditabar; Muzammil Ali; Joseph Roys; Edward M Wolin; Thomas M OʼDorisio; David Ranganathan; Izabela Tworowska; Jonathan R Strosberg; Ebrahim S Delpassand
Journal:  Clin Nucl Med       Date:  2017-06       Impact factor: 7.794

4.  Nothing new under the nuclear sun: towards 80 years of theranostics in nuclear medicine.

Authors:  Frederik A Verburg; Alexander Heinzel; Heribert Hänscheid; Felix M Mottaghy; Markus Luster; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-06       Impact factor: 9.236

Review 5.  Diagnosis and therapy are walking together on radiopeptides' avenue.

Authors:  Luigi Mansi; Irene Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04       Impact factor: 9.236

6.  [Neuroendocrine tumor therapy (NETTER-1) trial: 177Lu-DOTA-TATE for neuroendocrine tumors].

Authors:  T Derlin
Journal:  Radiologe       Date:  2017-05       Impact factor: 0.635

Review 7.  [177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors.

Authors:  Daniel M Halperin; Arvind Dasari; James C Yao
Journal:  Future Oncol       Date:  2016-01-13       Impact factor: 3.404

8.  Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Authors:  Jonathan Strosberg; Ghassan El-Haddad; Edward Wolin; Andrew Hendifar; James Yao; Beth Chasen; Erik Mittra; Pamela L Kunz; Matthew H Kulke; Heather Jacene; David Bushnell; Thomas M O'Dorisio; Richard P Baum; Harshad R Kulkarni; Martyn Caplin; Rachida Lebtahi; Timothy Hobday; Ebrahim Delpassand; Eric Van Cutsem; Al Benson; Rajaventhan Srirajaskanthan; Marianne Pavel; Jaime Mora; Jordan Berlin; Enrique Grande; Nicholas Reed; Ettore Seregni; Kjell Öberg; Maribel Lopera Sierra; Paola Santoro; Thomas Thevenet; Jack L Erion; Philippe Ruszniewski; Dik Kwekkeboom; Eric Krenning
Journal:  N Engl J Med       Date:  2017-01-12       Impact factor: 91.245

Review 9.  The Landmark Series: Neuroendocrine Tumor Liver Metastases.

Authors:  Alexandra Gangi; James R Howe
Journal:  Ann Surg Oncol       Date:  2020-07-06       Impact factor: 5.344

Review 10.  Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.

Authors:  Giuseppe Lo Russo; Sara Pusceddu; Natalie Prinzi; Martina Imbimbo; Claudia Proto; Diego Signorelli; Milena Vitali; Monica Ganzinelli; Marco Maccauro; Roberto Buzzoni; Ettore Seregni; Filippo de Braud; Marina Chiara Garassino
Journal:  Tumour Biol       Date:  2016-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.